Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 20/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21400059 | 0.95 | AGTR2 (1.00) | AGTR2 | |
| SCHEMBL23032242 | 0.88 | AGTR2 (0.72) | AGTR2 | |
| SCHEMBL23032510 | 0.84 | AGTR2 (0.65) | AGTR2 | |
| SCHEMBL21400356 | 0.84 | AGTR2 (0.79) | AGTR2 | |
| SCHEMBL21400117 | 0.83 | AGTR2 (0.78) | AGTR2 | |
| SCHEMBL22917166 | 0.80 | AGTR2 (0.70) | AGTR2 | |
| SCHEMBL21400055 | 0.76 | AGTR2 (0.67) | AGTR2 | |
| SCHEMBL29883283 | 0.76 | AGTR2 (0.67) | AGTR2 | |
| SCHEMBL23032053 | 0.75 | AGTR2 (0.88) | AGTR2 | |
| SCHEMBL22917382 | 0.74 | AGTR2 (0.73) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | AGTR2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.